LNSR
LENSAR, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
-2.81
P/S
1.24
EV/EBITDA
-3.62
DCF Value
$-61.69
FCF Yield
-20.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
46.4%
Operating Margin
-40.5%
Net Margin
-58.7%
ROE
197.2%
ROA
-51.8%
ROIC
-74.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $16.0M | $-1.5M | $-0.12 |
| FY 2025 | $58.4M | $-34.3M | $-2.87 |
| Q3 2025 | $14.3M | $-3.7M | $-0.31 |
| Q2 2025 | $13.9M | $-1.8M | $-0.15 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.98
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company was incorporated in 2004 and is headquartered in Orlando, Florida.